Home
About
Overview
Sharing Data
ORCID
Help
History (11)
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
McGuinn, Laura
Reversible amyloids of pyruvate kinase couple cell metabolism and stress granule disassembly.
Overview to Challenges in IBD 2024-2029.
Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate.
See All 11 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate.
Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate. Am J Gastroenterol. 2020 08; 115(8):1298.
View in:
PubMed
subject areas
Aged, 80 and over
Anemia
Antidiarrheals
Betacoronavirus
Bismuth
Blood Sedimentation
Coronavirus Infections
Cough
C-Reactive Protein
Crohn Disease
Diarrhea
Humans
Lymphopenia
Male
Organometallic Compounds
Pandemics
Pneumonia, Viral
Salicylates
Treatment Outcome
authors with profiles
David Rubin